Cerebras Enables Pharma and Energy R&D

This customer mix shows Cerebras had broken out of the national lab niche and into industries where faster model training can change billion dollar R&D decisions. Drug discovery teams use these systems to train foundation models on genomics and epigenomics data, while energy teams use them for seismic and subsurface simulations. That matters because these buyers spend against concrete research budgets, not experimental AI line items, and they buy when speed changes the pace of discovery.

• In pharma, the workload is not generic chatbot AI. GSK used Cerebras for epigenomic language models, which learn patterns in DNA regulation to help identify promising drug targets. AstraZeneca was also cited as a pharma customer, with Cerebras used to cut model training from weeks on GPU clusters to days.
  1 cerebras 4 sacra 5 wikipedia
• In energy, the fit is similarly specific. TotalEnergies selected Cerebras for multi energy research, and Cerebras reported more than 100x improvement on finite difference seismic benchmarks. These are large numerical simulations used to map underground structures and decide where to explore, drill, or store CO2.
  2 cerebras 6 anl 7 sacra
• This is a different motion from Nvidia's broad developer platform. Cerebras won where a small number of expensive jobs dominate the budget, and where keeping a giant model or simulation on one wafer scale chip reduces the delays and power cost of shuttling data across many GPUs.
  3 sacra 7 sacra

Going forward, this enterprise foothold is the bridge into a larger AI infrastructure business. Once a chip vendor is trusted for mission critical science workloads inside pharma and energy, it can expand from selling boxes for a few flagship teams into cloud access, recurring usage, and eventually broader model training and inference across the company.